Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Confluent starts pivotal anti-adhesion US trial:

This article was originally published in Clinica

Executive Summary

Confluent Surgical has begun a pivotal trial in the US to assess its sprayable gel as a means of preventing pelvic adhesions following laparoscopic surgery in women. Early studies have shown that the product - SprayGel - remains in place as a barrier for five to seven days, the period when adhesions normally form, says the Waltham, Massachusetts firm. The company notes that adhesions are estimated to affect over two million women and men in the US, where the potential market for abdominopelvic adhesion management is $400-$500m. SprayGel is currently available in Europe and Australia.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT066984

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel